Dainippon Sumitomo seeks expanded China presence with amrubicin filing
This article was originally published in Scrip
Executive Summary
In a move aimed at building its business in a key emerging market, Japan's Dainippon Sumitomo Pharma (DSP) has filed an application in China for the approval of amrubicin as a first-line treatment for small cell lung cancer.